Reappraising the clinical impact of mepolizumab

Brian J. Lipworth; Sunny Jabbal

doi:10.1016/S2213-2600(17)30183-2

Reappraising the clinical impact of mepolizumab

Brian J. Lipworth (Lead / Corresponding author), Sunny Jabbal

Research output: Contribution to journal › Letter › peer-review

175 Downloads (Pure)

Original language	English
Article number	e20
Number of pages	1
Journal	Lancet
Volume	5
Issue number	6
Early online date	26 May 2017
DOIs	https://doi.org/10.1016/S2213-2600(17)30183-2
Publication status	Published - Jun 2017

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1016/S2213-2600(17)30183-2

Author Accepted Manuscript
© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Accepted author manuscript, 172 KBLicence: CC BY-NC-ND

Cite this

@article{4f73a65cb8f0479da57e841c1e8a72c7,

title = "Reappraising the clinical impact of mepolizumab",

author = "Lipworth, {Brian J.} and Sunny Jabbal",

note = "BJL reports grants from AstraZeneca and Sanofi, and grants, personal fees, and other from Chiesi and Teva, relevant to the submitted work; and personal fees from Dr Reddys, Cipla, Lupin, and Sandoz, grants and personal fees from Meda, grants, personal fees, and other from Boehringer Ingelheim, and grants from Almirral, outside of the submitted work. His son is an employee of Boehringer Ingelheim. SJ reports personal fees and non-financial support from Chiesi and AstraZeneca, and non-financial support and other from Napp, relevant to the submitted work; and personal fees and non-financial support from Pfizer, outside of the submitted work",

year = "2017",

month = jun,

doi = "10.1016/S2213-2600(17)30183-2",

language = "English",

volume = "5",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Reappraising the clinical impact of mepolizumab

AU - Lipworth, Brian J.

AU - Jabbal, Sunny

N1 - BJL reports grants from AstraZeneca and Sanofi, and grants, personal fees, and other from Chiesi and Teva, relevant to the submitted work; and personal fees from Dr Reddys, Cipla, Lupin, and Sandoz, grants and personal fees from Meda, grants, personal fees, and other from Boehringer Ingelheim, and grants from Almirral, outside of the submitted work. His son is an employee of Boehringer Ingelheim. SJ reports personal fees and non-financial support from Chiesi and AstraZeneca, and non-financial support and other from Napp, relevant to the submitted work; and personal fees and non-financial support from Pfizer, outside of the submitted work

PY - 2017/6

Y1 - 2017/6

UR - http://www.scopus.com/inward/record.url?scp=85019717583&partnerID=8YFLogxK

U2 - 10.1016/S2213-2600(17)30183-2

DO - 10.1016/S2213-2600(17)30183-2

M3 - Letter

AN - SCOPUS:85019717583

SN - 0140-6736

VL - 5

JO - Lancet

JF - Lancet

IS - 6

M1 - e20

ER -

Reappraising the clinical impact of mepolizumab

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this